Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Hypersensitivity | 117 | 2024 | 918 | 25.360 |
Why?
|
Anaphylaxis | 84 | 2024 | 758 | 20.020 |
Why?
|
Desensitization, Immunologic | 85 | 2024 | 557 | 16.380 |
Why?
|
Mastocytosis | 44 | 2024 | 150 | 13.720 |
Why?
|
Mast Cells | 72 | 2024 | 1392 | 9.610 |
Why?
|
Mastocytosis, Systemic | 23 | 2024 | 102 | 7.070 |
Why?
|
Tryptases | 33 | 2023 | 176 | 5.460 |
Why?
|
Hypersensitivity | 27 | 2024 | 1167 | 4.530 |
Why?
|
Skin Tests | 37 | 2023 | 638 | 3.170 |
Why?
|
Penicillins | 11 | 2024 | 403 | 2.880 |
Why?
|
Immunoglobulin E | 33 | 2023 | 1505 | 2.730 |
Why?
|
Mastocytosis, Cutaneous | 7 | 2020 | 14 | 2.450 |
Why?
|
Insect Bites and Stings | 6 | 2023 | 71 | 2.280 |
Why?
|
Antineoplastic Agents | 32 | 2023 | 13632 | 2.260 |
Why?
|
Hymenoptera | 7 | 2023 | 14 | 2.150 |
Why?
|
Antibodies, Monoclonal | 22 | 2022 | 9187 | 2.060 |
Why?
|
Arthropod Venoms | 5 | 2023 | 11 | 1.950 |
Why?
|
Taxoids | 10 | 2021 | 668 | 1.730 |
Why?
|
Basophils | 10 | 2020 | 407 | 1.650 |
Why?
|
Hypersensitivity, Immediate | 10 | 2022 | 348 | 1.590 |
Why?
|
Carboplatin | 7 | 2023 | 793 | 1.570 |
Why?
|
Hypersensitivity, Delayed | 6 | 2021 | 490 | 1.550 |
Why?
|
Allergens | 13 | 2023 | 1433 | 1.490 |
Why?
|
Biological Factors | 3 | 2017 | 158 | 1.420 |
Why?
|
Receptors, IgE | 7 | 2023 | 375 | 1.370 |
Why?
|
Biological Products | 5 | 2022 | 915 | 1.360 |
Why?
|
Basophil Degranulation Test | 4 | 2019 | 20 | 1.280 |
Why?
|
Pharmaceutical Preparations | 3 | 2021 | 1086 | 1.230 |
Why?
|
Urticaria Pigmentosa | 3 | 2019 | 16 | 1.180 |
Why?
|
Paclitaxel | 6 | 2020 | 1730 | 1.180 |
Why?
|
Anti-Allergic Agents | 7 | 2021 | 153 | 1.170 |
Why?
|
Humans | 261 | 2024 | 761222 | 1.140 |
Why?
|
Vaccination | 6 | 2022 | 3369 | 1.110 |
Why?
|
Blister | 3 | 2019 | 86 | 1.060 |
Why?
|
Pruritus | 2 | 2024 | 378 | 1.060 |
Why?
|
Angioedema | 3 | 2017 | 184 | 1.030 |
Why?
|
Postural Orthostatic Tachycardia Syndrome | 2 | 2024 | 51 | 1.010 |
Why?
|
Platinum Compounds | 2 | 2016 | 95 | 1.010 |
Why?
|
Receptors, Neuropeptide | 1 | 2024 | 106 | 0.910 |
Why?
|
Epinephrine | 10 | 2022 | 791 | 0.890 |
Why?
|
beta-Lactams | 4 | 2023 | 156 | 0.850 |
Why?
|
Wasp Venoms | 3 | 2019 | 21 | 0.830 |
Why?
|
Platinum | 2 | 2021 | 220 | 0.800 |
Why?
|
Anti-Bacterial Agents | 19 | 2024 | 7407 | 0.770 |
Why?
|
Drug Eruptions | 4 | 2019 | 335 | 0.760 |
Why?
|
Intraoperative Complications | 4 | 2018 | 1164 | 0.750 |
Why?
|
Proto-Oncogene Proteins c-kit | 9 | 2024 | 726 | 0.740 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 12 | 2020 | 2270 | 0.730 |
Why?
|
Histamine Antagonists | 4 | 2020 | 93 | 0.720 |
Why?
|
Neoplasms | 17 | 2024 | 22142 | 0.710 |
Why?
|
Urticaria | 3 | 2021 | 150 | 0.710 |
Why?
|
Leukotriene Antagonists | 2 | 2019 | 124 | 0.700 |
Why?
|
Amoxicillin | 4 | 2023 | 181 | 0.670 |
Why?
|
Organoplatinum Compounds | 5 | 2013 | 407 | 0.660 |
Why?
|
Phenotype | 12 | 2024 | 16575 | 0.650 |
Why?
|
Bacitracin | 1 | 2018 | 24 | 0.640 |
Why?
|
Vaccines, Synthetic | 2 | 2022 | 612 | 0.640 |
Why?
|
Polyethylene Glycols | 2 | 2024 | 1187 | 0.630 |
Why?
|
Viral Vaccines | 2 | 2021 | 593 | 0.630 |
Why?
|
Antigens | 5 | 2017 | 1441 | 0.610 |
Why?
|
Doxorubicin | 2 | 2024 | 2224 | 0.600 |
Why?
|
Actins | 2 | 2023 | 2046 | 0.580 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2023 | 614 | 0.580 |
Why?
|
Ovarian Neoplasms | 7 | 2016 | 4872 | 0.580 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2024 | 1249 | 0.560 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2024 | 5666 | 0.560 |
Why?
|
Food Hypersensitivity | 7 | 2018 | 726 | 0.550 |
Why?
|
Allergy and Immunology | 3 | 2019 | 177 | 0.550 |
Why?
|
Meglumine | 1 | 2017 | 144 | 0.550 |
Why?
|
Perception | 3 | 2018 | 1198 | 0.550 |
Why?
|
Progesterone | 4 | 2022 | 742 | 0.530 |
Why?
|
Interleukin-6 | 3 | 2020 | 3210 | 0.530 |
Why?
|
Fibrinolysis | 1 | 2017 | 332 | 0.520 |
Why?
|
Connective Tissue Diseases | 1 | 2019 | 285 | 0.510 |
Why?
|
Breast Implantation | 1 | 2018 | 219 | 0.510 |
Why?
|
Acetates | 3 | 2019 | 319 | 0.510 |
Why?
|
Cystic Fibrosis | 2 | 2019 | 1283 | 0.500 |
Why?
|
Quinolones | 1 | 2019 | 378 | 0.500 |
Why?
|
Wasps | 1 | 2015 | 15 | 0.500 |
Why?
|
Anesthetics | 4 | 2018 | 523 | 0.500 |
Why?
|
Female | 85 | 2024 | 392552 | 0.490 |
Why?
|
Iduronidase | 1 | 2014 | 31 | 0.470 |
Why?
|
Autoimmune Diseases | 4 | 2022 | 2244 | 0.460 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3093 | 0.460 |
Why?
|
Goals | 1 | 2019 | 710 | 0.460 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3215 | 0.460 |
Why?
|
Mucopolysaccharidosis I | 1 | 2014 | 52 | 0.460 |
Why?
|
Antirheumatic Agents | 2 | 2015 | 1369 | 0.450 |
Why?
|
Latex Hypersensitivity | 2 | 2003 | 14 | 0.440 |
Why?
|
Progestins | 4 | 2022 | 301 | 0.440 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2013 | 61 | 0.440 |
Why?
|
Organometallic Compounds | 1 | 2017 | 647 | 0.440 |
Why?
|
Adult | 55 | 2024 | 221120 | 0.440 |
Why?
|
Maytansine | 1 | 2014 | 86 | 0.430 |
Why?
|
Middle Aged | 54 | 2024 | 220858 | 0.430 |
Why?
|
Cisplatin | 3 | 2013 | 1652 | 0.420 |
Why?
|
Cross Reactions | 6 | 2021 | 819 | 0.420 |
Why?
|
Penicillanic Acid | 2 | 2024 | 41 | 0.410 |
Why?
|
Receptors, Immunologic | 6 | 2001 | 1408 | 0.410 |
Why?
|
Antineoplastic Agents, Phytogenic | 3 | 2006 | 620 | 0.380 |
Why?
|
Quinolines | 3 | 2019 | 764 | 0.380 |
Why?
|
BRCA2 Protein | 1 | 2016 | 797 | 0.380 |
Why?
|
Dermatitis, Atopic | 1 | 2019 | 731 | 0.380 |
Why?
|
Quality of Life | 11 | 2023 | 13367 | 0.380 |
Why?
|
Exanthema | 4 | 2024 | 503 | 0.380 |
Why?
|
Diarrhea | 4 | 2022 | 1316 | 0.370 |
Why?
|
Vaccines | 2 | 2019 | 835 | 0.370 |
Why?
|
Male | 63 | 2024 | 360703 | 0.370 |
Why?
|
Erythema | 1 | 2012 | 262 | 0.370 |
Why?
|
Cromolyn Sodium | 4 | 2019 | 78 | 0.360 |
Why?
|
Patient Preference | 1 | 2018 | 927 | 0.360 |
Why?
|
Animals | 37 | 2024 | 168089 | 0.360 |
Why?
|
Glucocorticoids | 2 | 2020 | 2159 | 0.350 |
Why?
|
Aspirin | 6 | 2019 | 3129 | 0.350 |
Why?
|
Disease Management | 6 | 2024 | 2507 | 0.340 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2017 | 1116 | 0.340 |
Why?
|
BRCA1 Protein | 1 | 2016 | 1149 | 0.340 |
Why?
|
Syndrome | 6 | 2024 | 3271 | 0.340 |
Why?
|
Genital Neoplasms, Female | 2 | 2005 | 533 | 0.330 |
Why?
|
Anesthesia | 3 | 2011 | 1591 | 0.320 |
Why?
|
Thalidomide | 1 | 2014 | 885 | 0.310 |
Why?
|
Skin | 7 | 2019 | 4473 | 0.310 |
Why?
|
Sulfides | 3 | 2019 | 168 | 0.310 |
Why?
|
Pandemics | 4 | 2022 | 8663 | 0.310 |
Why?
|
Intradermal Tests | 4 | 2018 | 43 | 0.300 |
Why?
|
Perioperative Care | 4 | 2014 | 1037 | 0.300 |
Why?
|
Severity of Illness Index | 8 | 2021 | 15841 | 0.300 |
Why?
|
Cyclopropanes | 3 | 2019 | 432 | 0.290 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2019 | 1462 | 0.290 |
Why?
|
Cefazolin | 2 | 2007 | 94 | 0.290 |
Why?
|
International Classification of Diseases | 3 | 2024 | 915 | 0.280 |
Why?
|
Antigens, Surface | 5 | 2001 | 1607 | 0.280 |
Why?
|
RNA, Messenger | 3 | 2022 | 12747 | 0.280 |
Why?
|
Asthma | 5 | 2020 | 6230 | 0.270 |
Why?
|
Mastocytoma | 1 | 2006 | 5 | 0.270 |
Why?
|
Famotidine | 2 | 2019 | 17 | 0.270 |
Why?
|
Aged | 28 | 2024 | 169292 | 0.250 |
Why?
|
Contrast Media | 3 | 2018 | 5311 | 0.250 |
Why?
|
Histamine | 4 | 2019 | 499 | 0.250 |
Why?
|
Eosinophilia | 2 | 2011 | 557 | 0.250 |
Why?
|
Membrane Glycoproteins | 6 | 2001 | 3696 | 0.250 |
Why?
|
Inflammation Mediators | 4 | 2012 | 1885 | 0.240 |
Why?
|
Immunologic Factors | 1 | 2014 | 1589 | 0.240 |
Why?
|
Anti-Asthmatic Agents | 3 | 2019 | 573 | 0.240 |
Why?
|
Infertility, Female | 1 | 2010 | 761 | 0.240 |
Why?
|
Cell Degranulation | 2 | 2024 | 277 | 0.230 |
Why?
|
Minocycline | 1 | 2005 | 169 | 0.230 |
Why?
|
Histamine H2 Antagonists | 2 | 2019 | 166 | 0.230 |
Why?
|
Consensus | 7 | 2024 | 3134 | 0.230 |
Why?
|
Bone Marrow | 7 | 2020 | 2911 | 0.220 |
Why?
|
Staurosporine | 2 | 2018 | 241 | 0.220 |
Why?
|
Granulocytes | 2 | 2024 | 550 | 0.220 |
Why?
|
Injections, Subcutaneous | 2 | 2017 | 672 | 0.220 |
Why?
|
Treatment Outcome | 18 | 2018 | 64681 | 0.220 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2010 | 2426 | 0.220 |
Why?
|
Retrospective Studies | 11 | 2024 | 80675 | 0.210 |
Why?
|
Mesenchymal Stem Cells | 1 | 2013 | 1645 | 0.210 |
Why?
|
Fertilization in Vitro | 1 | 2010 | 1292 | 0.210 |
Why?
|
Chemokines | 1 | 2006 | 956 | 0.200 |
Why?
|
Genetic Predisposition to Disease | 4 | 2021 | 17897 | 0.200 |
Why?
|
Child | 18 | 2023 | 80154 | 0.200 |
Why?
|
Gastrointestinal Diseases | 3 | 2021 | 1201 | 0.190 |
Why?
|
Immunoglobulin G | 3 | 2021 | 4537 | 0.190 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2023 | 411 | 0.190 |
Why?
|
Receptors, Vitronectin | 1 | 2001 | 46 | 0.190 |
Why?
|
Penicillin G | 1 | 2021 | 40 | 0.190 |
Why?
|
Leukotriene E4 | 2 | 2019 | 75 | 0.190 |
Why?
|
Breast Neoplasms | 4 | 2021 | 20982 | 0.190 |
Why?
|
Inflammation | 3 | 2022 | 10759 | 0.180 |
Why?
|
Common Variable Immunodeficiency | 1 | 2002 | 100 | 0.180 |
Why?
|
Biopsy | 6 | 2018 | 6781 | 0.180 |
Why?
|
Integrins | 3 | 2012 | 835 | 0.180 |
Why?
|
Sex Characteristics | 3 | 2021 | 2640 | 0.180 |
Why?
|
Dermatitis | 1 | 2022 | 202 | 0.180 |
Why?
|
Portugal | 1 | 2020 | 91 | 0.180 |
Why?
|
World Health Organization | 2 | 2024 | 1321 | 0.180 |
Why?
|
Salts | 1 | 2020 | 62 | 0.170 |
Why?
|
Military Medicine | 1 | 2022 | 184 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2024 | 677 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 3 | 2021 | 5665 | 0.170 |
Why?
|
Disease Susceptibility | 3 | 2024 | 1791 | 0.170 |
Why?
|
Pyrophosphatases | 2 | 2018 | 142 | 0.170 |
Why?
|
Shock, Cardiogenic | 1 | 2005 | 709 | 0.170 |
Why?
|
Cetirizine | 1 | 2019 | 7 | 0.170 |
Why?
|
Phosphoric Diester Hydrolases | 2 | 2018 | 201 | 0.160 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 12159 | 0.160 |
Why?
|
Tubulin | 1 | 2023 | 693 | 0.160 |
Why?
|
Immunologic Tests | 1 | 2019 | 104 | 0.160 |
Why?
|
Chloroquine | 1 | 2020 | 274 | 0.160 |
Why?
|
Prostaglandin D2 | 1 | 2019 | 108 | 0.160 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13386 | 0.160 |
Why?
|
Dinitrobenzenes | 2 | 2011 | 37 | 0.160 |
Why?
|
Histamine H1 Antagonists | 1 | 2019 | 101 | 0.160 |
Why?
|
Secretory Vesicles | 2 | 2012 | 127 | 0.160 |
Why?
|
Anesthesia, General | 3 | 2018 | 1174 | 0.150 |
Why?
|
Cephalosporins | 1 | 2019 | 198 | 0.150 |
Why?
|
Dermatofibrosarcoma | 1 | 2018 | 48 | 0.150 |
Why?
|
Quarantine | 1 | 2020 | 182 | 0.150 |
Why?
|
Autopsy | 1 | 2022 | 1010 | 0.150 |
Why?
|
Mutation | 4 | 2022 | 30004 | 0.150 |
Why?
|
Duodenum | 1 | 2021 | 491 | 0.150 |
Why?
|
Up-Regulation | 2 | 2017 | 4111 | 0.150 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2014 | 668 | 0.150 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 1076 | 0.150 |
Why?
|
Hydroxyurea | 1 | 2019 | 284 | 0.150 |
Why?
|
Clinical Protocols | 4 | 2014 | 1436 | 0.140 |
Why?
|
Adrenal Cortex Hormones | 5 | 2019 | 1878 | 0.140 |
Why?
|
Therapeutic Irrigation | 1 | 2018 | 293 | 0.140 |
Why?
|
Autonomic Nervous System | 1 | 2022 | 704 | 0.140 |
Why?
|
Aromatase Inhibitors | 1 | 2021 | 513 | 0.140 |
Why?
|
Bradykinin | 1 | 2017 | 205 | 0.140 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2018 | 190 | 0.140 |
Why?
|
Blood Coagulation | 2 | 2014 | 1156 | 0.140 |
Why?
|
Hereditary Autoinflammatory Diseases | 1 | 2017 | 42 | 0.140 |
Why?
|
Cytokines | 3 | 2023 | 7386 | 0.140 |
Why?
|
Flushing | 3 | 2011 | 52 | 0.130 |
Why?
|
Antibody Formation | 1 | 2021 | 1391 | 0.130 |
Why?
|
Enzyme Inhibitors | 2 | 2021 | 3702 | 0.130 |
Why?
|
Outpatients | 2 | 2020 | 1598 | 0.130 |
Why?
|
Young Adult | 13 | 2021 | 59222 | 0.130 |
Why?
|
Societies | 1 | 2017 | 107 | 0.130 |
Why?
|
Peptide Hydrolases | 3 | 1988 | 616 | 0.130 |
Why?
|
Inpatients | 2 | 2024 | 2545 | 0.130 |
Why?
|
Aged, 80 and over | 8 | 2021 | 58952 | 0.130 |
Why?
|
Stem Cell Factor | 1 | 1996 | 195 | 0.130 |
Why?
|
Multiple Myeloma | 1 | 2014 | 5145 | 0.130 |
Why?
|
Diphenhydramine | 2 | 2014 | 63 | 0.130 |
Why?
|
Risk | 2 | 2019 | 9616 | 0.130 |
Why?
|
Diagnosis, Differential | 9 | 2021 | 12976 | 0.130 |
Why?
|
STAT6 Transcription Factor | 2 | 2006 | 196 | 0.130 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 299 | 0.130 |
Why?
|
Gonadal Steroid Hormones | 1 | 2019 | 702 | 0.130 |
Why?
|
Trans-Activators | 1 | 2005 | 2846 | 0.120 |
Why?
|
Immunoglobulins | 2 | 1999 | 850 | 0.120 |
Why?
|
Risk Factors | 11 | 2020 | 74241 | 0.120 |
Why?
|
RNA, Viral | 1 | 2023 | 2839 | 0.120 |
Why?
|
Bone Marrow Examination | 1 | 2015 | 155 | 0.120 |
Why?
|
Health Care Costs | 2 | 2020 | 3239 | 0.120 |
Why?
|
Receptors, IgG | 2 | 1997 | 558 | 0.120 |
Why?
|
Cost of Illness | 2 | 2022 | 1936 | 0.120 |
Why?
|
Melphalan | 1 | 2016 | 420 | 0.120 |
Why?
|
Exercise | 2 | 2003 | 5874 | 0.110 |
Why?
|
Enzyme Replacement Therapy | 1 | 2014 | 80 | 0.110 |
Why?
|
Skin Diseases | 2 | 2021 | 1095 | 0.110 |
Why?
|
Pregnancy Complications | 2 | 2021 | 2949 | 0.110 |
Why?
|
Caspase 7 | 1 | 2013 | 50 | 0.110 |
Why?
|
Multigene Family | 2 | 1994 | 1075 | 0.110 |
Why?
|
Government Regulation | 1 | 2018 | 523 | 0.110 |
Why?
|
Antibiotic Prophylaxis | 1 | 2019 | 637 | 0.110 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1504 | 0.110 |
Why?
|
Complement Activation | 1 | 2015 | 445 | 0.110 |
Why?
|
Medicine | 1 | 2021 | 942 | 0.110 |
Why?
|
Phenytoin | 1 | 2014 | 190 | 0.110 |
Why?
|
Mice, Inbred BALB C | 5 | 2011 | 6200 | 0.110 |
Why?
|
Genes, Immunoglobulin | 1 | 1994 | 286 | 0.110 |
Why?
|
Chymases | 4 | 2007 | 73 | 0.110 |
Why?
|
Mast-Cell Sarcoma | 1 | 2012 | 46 | 0.110 |
Why?
|
Mice | 13 | 2023 | 81330 | 0.110 |
Why?
|
Thrombin | 2 | 2014 | 593 | 0.110 |
Why?
|
Anesthesia, Obstetrical | 2 | 2013 | 232 | 0.110 |
Why?
|
Sequence Deletion | 1 | 2017 | 1487 | 0.100 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 464 | 0.100 |
Why?
|
Fibrin | 2 | 2014 | 507 | 0.100 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2015 | 246 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2017 | 1838 | 0.100 |
Why?
|
Culture Media, Conditioned | 1 | 2013 | 522 | 0.100 |
Why?
|
Immune Tolerance | 2 | 2019 | 2307 | 0.100 |
Why?
|
Time Factors | 5 | 2014 | 39957 | 0.100 |
Why?
|
Estrogens | 1 | 2019 | 1522 | 0.100 |
Why?
|
Fibrinogen | 2 | 2014 | 888 | 0.100 |
Why?
|
Surgical Procedures, Operative | 1 | 2003 | 1923 | 0.100 |
Why?
|
Nerve Tissue Proteins | 1 | 2024 | 4404 | 0.100 |
Why?
|
Rifampin | 1 | 2014 | 338 | 0.100 |
Why?
|
Child, Preschool | 6 | 2021 | 42225 | 0.100 |
Why?
|
Prevalence | 3 | 2019 | 15721 | 0.100 |
Why?
|
Adolescent | 12 | 2021 | 88300 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2018 | 4014 | 0.100 |
Why?
|
Anti-Infective Agents | 1 | 2019 | 983 | 0.100 |
Why?
|
Leukocytes | 2 | 2012 | 2025 | 0.090 |
Why?
|
gamma-Globulins | 1 | 2011 | 119 | 0.090 |
Why?
|
Shock | 1 | 2014 | 314 | 0.090 |
Why?
|
Caspase 3 | 1 | 2013 | 730 | 0.090 |
Why?
|
Cerebrovascular Circulation | 1 | 2021 | 2725 | 0.090 |
Why?
|
Medical Oncology | 2 | 2024 | 2320 | 0.090 |
Why?
|
Life Expectancy | 1 | 2018 | 1242 | 0.090 |
Why?
|
Infant | 7 | 2019 | 36170 | 0.090 |
Why?
|
Fluid Therapy | 1 | 2015 | 578 | 0.090 |
Why?
|
Nanoparticles | 2 | 2022 | 1959 | 0.090 |
Why?
|
Latent Tuberculosis | 1 | 2014 | 224 | 0.090 |
Why?
|
Fluorobenzenes | 1 | 2012 | 179 | 0.090 |
Why?
|
Heart Rate | 1 | 2022 | 4197 | 0.090 |
Why?
|
Prednisone | 2 | 2018 | 1565 | 0.090 |
Why?
|
Recurrence | 3 | 2020 | 8457 | 0.090 |
Why?
|
Ranitidine | 1 | 2010 | 34 | 0.090 |
Why?
|
Leukotrienes | 1 | 2012 | 230 | 0.090 |
Why?
|
Disease Progression | 4 | 2020 | 13511 | 0.090 |
Why?
|
Propylene Glycol | 1 | 2010 | 30 | 0.090 |
Why?
|
Respiratory Insufficiency | 1 | 2019 | 1232 | 0.090 |
Why?
|
Bone Marrow Cells | 4 | 2006 | 2410 | 0.090 |
Why?
|
Immunoglobulin A | 2 | 2011 | 979 | 0.090 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1662 | 0.080 |
Why?
|
Excipients | 1 | 2010 | 98 | 0.080 |
Why?
|
Immunotherapy | 3 | 2019 | 4642 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 36415 | 0.080 |
Why?
|
Spondylitis, Ankylosing | 1 | 2011 | 155 | 0.080 |
Why?
|
United States | 9 | 2022 | 72341 | 0.080 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2011 | 355 | 0.080 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3149 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2010 | 6304 | 0.080 |
Why?
|
Virus Diseases | 1 | 2015 | 716 | 0.080 |
Why?
|
Parabens | 1 | 2010 | 114 | 0.080 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2014 | 556 | 0.080 |
Why?
|
Transplantation Conditioning | 1 | 2016 | 1591 | 0.080 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 2217 | 0.080 |
Why?
|
Immunization | 2 | 2021 | 1218 | 0.080 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2005 | 359 | 0.080 |
Why?
|
Immune System Diseases | 1 | 2011 | 255 | 0.080 |
Why?
|
Signal Transduction | 5 | 2024 | 23419 | 0.080 |
Why?
|
Health Personnel | 1 | 2022 | 3337 | 0.080 |
Why?
|
Irritable Bowel Syndrome | 1 | 2014 | 453 | 0.080 |
Why?
|
Drug Prescriptions | 1 | 2018 | 1668 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2011 | 585 | 0.080 |
Why?
|
Asthma, Aspirin-Induced | 1 | 2012 | 202 | 0.080 |
Why?
|
Intestinal Mucosa | 2 | 2021 | 3031 | 0.070 |
Why?
|
Family | 1 | 2018 | 3192 | 0.070 |
Why?
|
Patient Care Team | 1 | 2018 | 2515 | 0.070 |
Why?
|
Venoms | 2 | 2018 | 94 | 0.070 |
Why?
|
Patients | 1 | 2013 | 906 | 0.070 |
Why?
|
Cysteine | 1 | 2012 | 888 | 0.070 |
Why?
|
Transfection | 2 | 2013 | 5748 | 0.070 |
Why?
|
Serine Endopeptidases | 3 | 2006 | 1022 | 0.070 |
Why?
|
Algorithms | 2 | 2020 | 14025 | 0.070 |
Why?
|
Biomedical Research | 2 | 2019 | 3434 | 0.070 |
Why?
|
Vomiting | 1 | 2010 | 650 | 0.070 |
Why?
|
Blood Pressure | 1 | 2022 | 8479 | 0.070 |
Why?
|
Delphi Technique | 2 | 2021 | 848 | 0.070 |
Why?
|
Liposomes | 2 | 2022 | 783 | 0.070 |
Why?
|
Lipodystrophy | 1 | 2007 | 145 | 0.070 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 694 | 0.070 |
Why?
|
Risk Assessment | 2 | 2020 | 24022 | 0.070 |
Why?
|
Nasal Polyps | 1 | 2012 | 395 | 0.070 |
Why?
|
Emotions | 1 | 2018 | 2742 | 0.070 |
Why?
|
Emergency Service, Hospital | 3 | 2023 | 7865 | 0.070 |
Why?
|
Carboxylic Ester Hydrolases | 1 | 2006 | 99 | 0.070 |
Why?
|
Blotting, Western | 1 | 2013 | 5032 | 0.070 |
Why?
|
Genome, Human | 1 | 2019 | 4423 | 0.060 |
Why?
|
Genetic Variation | 1 | 2021 | 6567 | 0.060 |
Why?
|
Liver Transplantation | 1 | 1998 | 2332 | 0.060 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4851 | 0.060 |
Why?
|
Picrates | 1 | 2005 | 13 | 0.060 |
Why?
|
Reference Standards | 1 | 2009 | 1005 | 0.060 |
Why?
|
Nasal Mucosa | 1 | 1988 | 413 | 0.060 |
Why?
|
Receptor, erbB-2 | 1 | 2015 | 2553 | 0.060 |
Why?
|
Leiomyoma | 1 | 2010 | 636 | 0.060 |
Why?
|
Hospitalization | 2 | 2022 | 10707 | 0.060 |
Why?
|
Immunophenotyping | 2 | 2021 | 1867 | 0.060 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 4909 | 0.060 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3253 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10756 | 0.060 |
Why?
|
Cell Line | 3 | 2019 | 15545 | 0.060 |
Why?
|
Lung | 3 | 2022 | 9979 | 0.060 |
Why?
|
Antibodies, Neoplasm | 1 | 2006 | 282 | 0.060 |
Why?
|
Hysterectomy | 1 | 2010 | 857 | 0.060 |
Why?
|
Perioperative Period | 2 | 2019 | 252 | 0.060 |
Why?
|
Stem Cells | 1 | 1997 | 3517 | 0.060 |
Why?
|
Heparin | 1 | 2012 | 1632 | 0.060 |
Why?
|
Models, Immunological | 1 | 2006 | 515 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2024 | 90 | 0.060 |
Why?
|
Insulin | 2 | 2009 | 6588 | 0.060 |
Why?
|
Anticonvulsants | 1 | 2014 | 1910 | 0.060 |
Why?
|
Calcium | 2 | 2018 | 5719 | 0.060 |
Why?
|
Peptides | 2 | 2014 | 4353 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 8519 | 0.050 |
Why?
|
Asthma, Exercise-Induced | 1 | 2003 | 23 | 0.050 |
Why?
|
Sulfonamides | 1 | 2012 | 1977 | 0.050 |
Why?
|
Myocardial Revascularization | 1 | 2006 | 794 | 0.050 |
Why?
|
Research | 2 | 2021 | 1976 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12052 | 0.050 |
Why?
|
Hemorrhage | 1 | 2014 | 3422 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15308 | 0.050 |
Why?
|
Vitronectin | 1 | 2001 | 41 | 0.050 |
Why?
|
Ukraine | 1 | 2022 | 149 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4822 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2011 | 18927 | 0.050 |
Why?
|
Bacterial Infections | 1 | 2009 | 1390 | 0.050 |
Why?
|
Triazines | 1 | 2023 | 311 | 0.050 |
Why?
|
Vegetables | 1 | 1986 | 1192 | 0.050 |
Why?
|
Prognosis | 3 | 2014 | 29688 | 0.050 |
Why?
|
Blood Platelets | 1 | 2012 | 2477 | 0.050 |
Why?
|
Uterine Neoplasms | 1 | 2010 | 1420 | 0.050 |
Why?
|
Logistic Models | 1 | 2015 | 13249 | 0.050 |
Why?
|
Iron | 1 | 2009 | 1791 | 0.050 |
Why?
|
Terminology as Topic | 2 | 2020 | 1528 | 0.050 |
Why?
|
Anti-Inflammatory Agents | 1 | 2010 | 1812 | 0.040 |
Why?
|
Pyrimidines | 1 | 2012 | 3027 | 0.040 |
Why?
|
Lymphoid Tissue | 1 | 2002 | 445 | 0.040 |
Why?
|
Diet | 1 | 2018 | 8048 | 0.040 |
Why?
|
Acne Vulgaris | 1 | 2005 | 349 | 0.040 |
Why?
|
Florida | 1 | 2021 | 429 | 0.040 |
Why?
|
Pregnancy Outcome | 1 | 2010 | 2923 | 0.040 |
Why?
|
Serum Sickness | 1 | 2019 | 27 | 0.040 |
Why?
|
Societies, Medical | 3 | 2018 | 3923 | 0.040 |
Why?
|
Binding, Competitive | 1 | 2001 | 1140 | 0.040 |
Why?
|
Pyrazolones | 1 | 2019 | 8 | 0.040 |
Why?
|
Myeloablative Agonists | 1 | 2020 | 209 | 0.040 |
Why?
|
Apoptosis | 2 | 2013 | 9478 | 0.040 |
Why?
|
Nanomedicine | 1 | 2022 | 289 | 0.040 |
Why?
|
Cesarean Section | 2 | 2021 | 1399 | 0.040 |
Why?
|
Sex Factors | 1 | 2013 | 10553 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2021 | 1059 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5809 | 0.040 |
Why?
|
Pregnancy | 4 | 2021 | 29893 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2017 | 5842 | 0.040 |
Why?
|
Glycoproteins | 1 | 2006 | 2203 | 0.040 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 1 | 2018 | 105 | 0.040 |
Why?
|
Bone Diseases | 1 | 2002 | 418 | 0.040 |
Why?
|
Antigens, Neoplasm | 1 | 2006 | 1985 | 0.040 |
Why?
|
Peritoneal Neoplasms | 1 | 2004 | 710 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2014 | 8531 | 0.040 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2021 | 494 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3245 | 0.040 |
Why?
|
Expert Testimony | 1 | 2020 | 365 | 0.040 |
Why?
|
Consensus Sequence | 2 | 1996 | 362 | 0.040 |
Why?
|
Diet Therapy | 1 | 2018 | 151 | 0.040 |
Why?
|
Neuromuscular Agents | 1 | 2019 | 148 | 0.040 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 4190 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 1 | 2012 | 3753 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 16954 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2009 | 2527 | 0.030 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2006 | 1074 | 0.030 |
Why?
|
Pyrroles | 1 | 2023 | 1124 | 0.030 |
Why?
|
Anesthetics, Local | 1 | 2003 | 998 | 0.030 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 368 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2871 | 0.030 |
Why?
|
Immunologic Surveillance | 1 | 2017 | 92 | 0.030 |
Why?
|
Emergency Medical Services | 2 | 2021 | 1920 | 0.030 |
Why?
|
Immunity | 1 | 2022 | 996 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2017 | 473 | 0.030 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2015 | 63 | 0.030 |
Why?
|
Antigens, CD | 1 | 2006 | 4009 | 0.030 |
Why?
|
Vitamin D | 2 | 2020 | 3301 | 0.030 |
Why?
|
Haptens | 1 | 2015 | 163 | 0.030 |
Why?
|
Diphosphonates | 1 | 2020 | 634 | 0.030 |
Why?
|
Endometrial Neoplasms | 1 | 2004 | 1366 | 0.030 |
Why?
|
DNA, Complementary | 2 | 1999 | 1989 | 0.030 |
Why?
|
Dideoxynucleosides | 1 | 2015 | 135 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 931 | 0.030 |
Why?
|
Carbamazepine | 1 | 2015 | 224 | 0.030 |
Why?
|
Bone Diseases, Metabolic | 1 | 2018 | 410 | 0.030 |
Why?
|
Minority Groups | 1 | 2022 | 1201 | 0.030 |
Why?
|
Vasoconstrictor Agents | 1 | 2018 | 655 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2018 | 2813 | 0.030 |
Why?
|
Connective Tissue Cells | 1 | 1994 | 49 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 9278 | 0.030 |
Why?
|
Ligands | 1 | 2001 | 3264 | 0.030 |
Why?
|
Brazil | 1 | 2018 | 1228 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10516 | 0.030 |
Why?
|
History, 20th Century | 1 | 2022 | 2765 | 0.030 |
Why?
|
Rifabutin | 1 | 2014 | 59 | 0.030 |
Why?
|
Headache | 1 | 2002 | 1255 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26072 | 0.030 |
Why?
|
Classification | 1 | 1994 | 128 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 2 | 1996 | 2740 | 0.030 |
Why?
|
Glucosephosphate Dehydrogenase Deficiency | 1 | 2014 | 95 | 0.030 |
Why?
|
Drug Dosage Calculations | 1 | 2014 | 117 | 0.030 |
Why?
|
Gene Expression | 3 | 2015 | 7571 | 0.030 |
Why?
|
Radiography | 2 | 2017 | 6974 | 0.030 |
Why?
|
Respiratory Sounds | 1 | 2017 | 702 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 1997 | 1435 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 746 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 307 | 0.030 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1994 | 1053 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 10218 | 0.030 |
Why?
|
Cost Savings | 1 | 2018 | 911 | 0.030 |
Why?
|
Pyrazoles | 1 | 2023 | 2010 | 0.030 |
Why?
|
Exons | 2 | 1999 | 2380 | 0.030 |
Why?
|
Myocardium | 1 | 2005 | 4746 | 0.030 |
Why?
|
Homozygote | 1 | 2017 | 1775 | 0.030 |
Why?
|
Needs Assessment | 1 | 2018 | 1141 | 0.030 |
Why?
|
Incidence | 2 | 2018 | 21366 | 0.020 |
Why?
|
Isoniazid | 1 | 2014 | 283 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2016 | 617 | 0.020 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 1992 | 317 | 0.020 |
Why?
|
Antigen Presentation | 1 | 1997 | 1251 | 0.020 |
Why?
|
Esophagoscopy | 1 | 2014 | 398 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 11733 | 0.020 |
Why?
|
Physicians, Primary Care | 1 | 2018 | 619 | 0.020 |
Why?
|
Lung Diseases | 1 | 2002 | 1910 | 0.020 |
Why?
|
Iodine Compounds | 1 | 2011 | 28 | 0.020 |
Why?
|
Th2 Cells | 1 | 2017 | 1071 | 0.020 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2012 | 128 | 0.020 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2011 | 23 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2001 | 6504 | 0.020 |
Why?
|
Codeine | 1 | 2011 | 51 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3875 | 0.020 |
Why?
|
Bronchoconstriction | 1 | 2012 | 141 | 0.020 |
Why?
|
Pregnancy Trimester, Third | 1 | 2013 | 583 | 0.020 |
Why?
|
Egg Hypersensitivity | 1 | 2011 | 47 | 0.020 |
Why?
|
Antigens, Differentiation | 1 | 1994 | 918 | 0.020 |
Why?
|
Asymptomatic Diseases | 1 | 2014 | 588 | 0.020 |
Why?
|
Bone Density Conservation Agents | 1 | 2018 | 793 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2016 | 2112 | 0.020 |
Why?
|
Mucous Membrane | 1 | 1994 | 659 | 0.020 |
Why?
|
India | 1 | 2017 | 2287 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2018 | 1605 | 0.020 |
Why?
|
Spleen | 1 | 1996 | 2290 | 0.020 |
Why?
|
Labor, Obstetric | 1 | 2013 | 323 | 0.020 |
Why?
|
Neuromuscular Blocking Agents | 1 | 2011 | 129 | 0.020 |
Why?
|
Genes | 1 | 1994 | 1820 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2022 | 1847 | 0.020 |
Why?
|
Acute Disease | 1 | 2021 | 7226 | 0.020 |
Why?
|
Cell Count | 1 | 2014 | 1831 | 0.020 |
Why?
|
Age of Onset | 1 | 2017 | 3307 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2018 | 4822 | 0.020 |
Why?
|
HLA Antigens | 1 | 2015 | 1331 | 0.020 |
Why?
|
Cyclosporine | 1 | 1992 | 776 | 0.020 |
Why?
|
Species Specificity | 1 | 1994 | 2406 | 0.020 |
Why?
|
Amino Acid Sequence | 3 | 1999 | 13402 | 0.020 |
Why?
|
DNA Primers | 1 | 1994 | 2814 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 1996 | 1838 | 0.020 |
Why?
|
Dyspnea | 1 | 2017 | 1347 | 0.020 |
Why?
|
Learning | 1 | 2019 | 1737 | 0.020 |
Why?
|
Isoenzymes | 1 | 2014 | 1682 | 0.020 |
Why?
|
Ribs | 1 | 2011 | 260 | 0.020 |
Why?
|
Nasal Provocation Tests | 1 | 1988 | 9 | 0.020 |
Why?
|
Cell Division | 1 | 1996 | 4451 | 0.020 |
Why?
|
Receptors, Fc | 1 | 1992 | 537 | 0.020 |
Why?
|
Protein Multimerization | 1 | 2014 | 974 | 0.020 |
Why?
|
Tacrolimus | 1 | 1992 | 736 | 0.020 |
Why?
|
Protein Binding | 1 | 2001 | 9297 | 0.020 |
Why?
|
Antibodies | 1 | 2017 | 2415 | 0.020 |
Why?
|
Osteoporosis | 1 | 2018 | 1604 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 1994 | 4167 | 0.020 |
Why?
|
Communicable Diseases | 1 | 2017 | 873 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9327 | 0.020 |
Why?
|
Meat | 1 | 2011 | 584 | 0.020 |
Why?
|
Anesthetics, Intravenous | 1 | 2011 | 394 | 0.020 |
Why?
|
Public Health | 1 | 2021 | 2672 | 0.020 |
Why?
|
Peanut Hypersensitivity | 1 | 2011 | 219 | 0.020 |
Why?
|
Morpholines | 1 | 2011 | 581 | 0.020 |
Why?
|
Seafood | 1 | 2011 | 393 | 0.020 |
Why?
|
Anticoagulants | 1 | 2003 | 4795 | 0.020 |
Why?
|
Fishes | 1 | 2011 | 600 | 0.020 |
Why?
|
Drug Resistance | 1 | 2014 | 1594 | 0.020 |
Why?
|
Edema | 1 | 2012 | 764 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2017 | 2731 | 0.020 |
Why?
|
Base Sequence | 2 | 1999 | 12404 | 0.020 |
Why?
|
Crohn Disease | 1 | 2000 | 2278 | 0.020 |
Why?
|
Radioallergosorbent Test | 1 | 1986 | 19 | 0.020 |
Why?
|
Cell Membrane | 1 | 1996 | 3661 | 0.020 |
Why?
|
Anesthesia, Spinal | 1 | 2010 | 279 | 0.020 |
Why?
|
Health Behavior | 1 | 2018 | 2641 | 0.020 |
Why?
|
Sodium Dodecyl Sulfate | 1 | 1986 | 124 | 0.020 |
Why?
|
Cell Fractionation | 1 | 1987 | 248 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2005 | 22128 | 0.020 |
Why?
|
Pollen | 1 | 1986 | 81 | 0.020 |
Why?
|
Thoracic Vertebrae | 1 | 2011 | 612 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2015 | 2549 | 0.020 |
Why?
|
Protein Conformation | 1 | 1994 | 3933 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2022 | 3354 | 0.020 |
Why?
|
Spain | 1 | 2007 | 489 | 0.020 |
Why?
|
Colonoscopy | 1 | 2014 | 1395 | 0.020 |
Why?
|
Alleles | 1 | 2017 | 6857 | 0.020 |
Why?
|
Histocytochemistry | 1 | 1987 | 697 | 0.020 |
Why?
|
Analgesia | 1 | 2010 | 461 | 0.020 |
Why?
|
Propofol | 1 | 2011 | 602 | 0.020 |
Why?
|
Bone Density | 1 | 2018 | 3546 | 0.020 |
Why?
|
Genetic Testing | 1 | 2018 | 3537 | 0.020 |
Why?
|
beta-N-Acetylhexosaminidases | 2 | 1996 | 44 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 1996 | 17598 | 0.020 |
Why?
|
Lymph Nodes | 1 | 1996 | 3461 | 0.020 |
Why?
|
Hypotension | 1 | 2011 | 879 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2011 | 1067 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1994 | 6067 | 0.010 |
Why?
|
Plant Proteins | 1 | 1986 | 374 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1986 | 1728 | 0.010 |
Why?
|
Analgesics | 1 | 2011 | 1068 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2012 | 3512 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3803 | 0.010 |
Why?
|
Health Surveys | 1 | 2013 | 4037 | 0.010 |
Why?
|
Immunoassay | 1 | 1987 | 743 | 0.010 |
Why?
|
Endopeptidases | 1 | 1987 | 766 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2013 | 2632 | 0.010 |
Why?
|
Attitude to Health | 1 | 2011 | 2026 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1998 | 4242 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18222 | 0.010 |
Why?
|
T-Lymphocytes | 2 | 2011 | 10203 | 0.010 |
Why?
|
Primary Health Care | 1 | 2018 | 4679 | 0.010 |
Why?
|
Internet | 1 | 2013 | 3096 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2012 | 2827 | 0.010 |
Why?
|
Epitopes | 1 | 2008 | 2504 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2021 | 26200 | 0.010 |
Why?
|
Physicians | 1 | 2019 | 4584 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11067 | 0.010 |
Why?
|
DNA | 1 | 1994 | 7189 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2011 | 5478 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20118 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2012 | 2746 | 0.010 |
Why?
|
Carrier Proteins | 1 | 1992 | 4935 | 0.010 |
Why?
|
Chronic Disease | 1 | 2014 | 9319 | 0.010 |
Why?
|
Rhinitis | 1 | 2007 | 747 | 0.010 |
Why?
|
Cell Differentiation | 1 | 1996 | 11512 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4567 | 0.010 |
Why?
|
Echocardiography | 1 | 2011 | 5006 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3198 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 7400 | 0.010 |
Why?
|
Electrocardiography | 1 | 2011 | 6387 | 0.010 |
Why?
|
Sinusitis | 1 | 2007 | 990 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 15920 | 0.010 |
Why?
|
Receptor Aggregation | 1 | 1996 | 72 | 0.010 |
Why?
|
Introns | 1 | 1999 | 968 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39127 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2012 | 14392 | 0.010 |
Why?
|
Conserved Sequence | 1 | 1999 | 1162 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 22174 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1994 | 11855 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2002 | 15521 | 0.010 |
Why?
|
Patient Selection | 1 | 2007 | 4246 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3089 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2007 | 3417 | 0.010 |
Why?
|
Amino Acid Isomerases | 1 | 1992 | 31 | 0.010 |
Why?
|
Peptidylprolyl Isomerase | 1 | 1992 | 97 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1996 | 2175 | 0.010 |
Why?
|
Tyrosine | 1 | 1996 | 1422 | 0.010 |
Why?
|
Calcineurin | 1 | 1992 | 229 | 0.010 |
Why?
|
Tacrolimus Binding Proteins | 1 | 1992 | 193 | 0.010 |
Why?
|
Calmodulin-Binding Proteins | 1 | 1992 | 233 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2007 | 8002 | 0.010 |
Why?
|
Exocytosis | 1 | 1992 | 320 | 0.010 |
Why?
|
Phosphoprotein Phosphatases | 1 | 1992 | 328 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20588 | 0.010 |
Why?
|
Models, Genetic | 1 | 1999 | 3430 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1999 | 5871 | 0.010 |
Why?
|
Penis | 1 | 1987 | 212 | 0.000 |
Why?
|
Cohort Studies | 1 | 2008 | 41496 | 0.000 |
Why?
|
Protease Inhibitors | 1 | 1987 | 752 | 0.000 |
Why?
|
Substrate Specificity | 1 | 1987 | 1768 | 0.000 |
Why?
|